Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Oncogenesis of Pancreatic Cancer: Where Are We
share announcement

Oncogenesis of Pancreatic Cancer: Where Are We

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 4839

Special Issue Editors

Dr. Surendra Shukla

E-Mail Website
Guest Editor
Department of Oncology Science, OU Health Stephenson Cancer Centre, Oklahoma City, OK 73104, USA
Interests: cancer; drug discovery; molecular biology; novel therapeutic strategies; human diseases; pancreatic cancer; liver cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Tuo Hu

E-Mail Website
Guest Editor
Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China
Interests: colorectal cancer; pancreatic cancer

Special Issue Information

Dear Colleagues,

Pancreatic cancer is a devastating disease with a 5-year survival rate of just 11% in the USA. It accounts for just 3% of all cancer cases but shares 7% of the total cancer-related deaths. There are several factors responsible for the high mortality of pancreatic cancer patients, such as: late detection, early metastasis, therapy resistance, and cancer-associated cachexia. In the last decade, despite the advancement of our knowledge on the pathogenesis of pancreatic cancer, much remains unexplored regarding the disease progression. A better understanding of the pathogenesis of pancreatic cancer may lead to better management of the disease, leading to improved survival of patients. The aim of the proposed Special Issue is to publish cutting-edge research articles and relevant review articles, which can help to improve our understanding of the progression of pancreatic cancer. I hope this Special Issue will be very useful for the research community and care providers.

Dr. Surendra Shukla
Dr. Tuo Hu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • molecular mechanism
  • animal models of pancreatic cancer
  • cancer pathogenesis
  • cancer and muscle wasting

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

19 pages, 6686 KiB  
Article
The m7G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling
by Jiancong Xie, Taiwei Mo, Ruibing Li, Hao Zhang, Guanzhan Liang, Tao Ma, Jing Chen, Hanlin Xie, Xiaofeng Wen, Tuo Hu, Zhenyu Xian and Weidong Pan
Cancers 2023, 15(22), 5454; https://doi.org/10.3390/cancers15225454 - 17 Nov 2023
Cited by 3 | Viewed by 1369
Abstract
PDAC is one of the most common malignant tumors worldwide. The difficulty of early diagnosis and lack of effective treatment are the main reasons for its poor prognosis. Therefore, it is urgent to identify novel diagnostic and therapeutic targets for PDAC patients. The [...] Read more.
PDAC is one of the most common malignant tumors worldwide. The difficulty of early diagnosis and lack of effective treatment are the main reasons for its poor prognosis. Therefore, it is urgent to identify novel diagnostic and therapeutic targets for PDAC patients. The m7G methylation is a common type of RNA modification that plays a pivotal role in regulating tumor development. However, the correlation between m7G regulatory genes and PDAC progression remains unclear. By integrating gene expression and related clinical information of PDAC patients from TCGA and GEO cohorts, m7G binding protein NCBP2 was found to be highly expressed in PDAC patients. More importantly, PDAC patients with high NCBP2 expression had a worse prognosis. Stable NCBP2-knockdown and overexpression PDAC cell lines were constructed to further perform in-vitro and in-vivo experiments. NCBP2-knockdown significantly inhibited PDAC cell proliferation, while overexpression of NCBP2 dramatically promoted PDAC cell growth. Mechanistically, NCBP2 enhanced the translation of c-JUN, which in turn activated MEK/ERK signaling to promote PDAC progression. In conclusion, our study reveals that m7G reader NCBP2 promotes PDAC progression by activating MEK/ERK pathway, which could serve as a novel therapeutic target for PDAC patients. Full article
(This article belongs to the Special Issue Oncogenesis of Pancreatic Cancer: Where Are We)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

22 pages, 2908 KiB  
Review
Extracellular Vesicular miRNA in Pancreatic Cancer: From Lab to Therapy
by Prashant Kumar Tiwari, Poojhaa Shanmugam, Vamika Karn, Saurabh Gupta, Richa Mishra, Sarvesh Rustagi, Mandeep Chouhan, Devvret Verma, Niraj Kumar Jha and Sanjay Kumar
Cancers 2024, 16(12), 2179; https://doi.org/10.3390/cancers16122179 - 8 Jun 2024
Cited by 1 | Viewed by 686
Abstract
Pancreatic cancer is a prevalent lethal gastrointestinal cancer that generally does not show any symptoms until it reaches advanced stages, resulting in a high mortality rate. People at high risk, such as those with a family history or chronic pancreatitis, do not have [...] Read more.
Pancreatic cancer is a prevalent lethal gastrointestinal cancer that generally does not show any symptoms until it reaches advanced stages, resulting in a high mortality rate. People at high risk, such as those with a family history or chronic pancreatitis, do not have a universally accepted screening protocol. Chemotherapy and radiotherapy demonstrate limited effectiveness in the management of pancreatic cancer, emphasizing the urgent need for innovative therapeutic strategies. Recent studies indicated that the complex interaction among pancreatic cancer cells within the dynamic microenvironment, comprising the extracellular matrix, cancer-associated cells, and diverse immune cells, intricately regulates the biological characteristics of the disease. Additionally, mounting evidence suggests that EVs play a crucial role as mediators in intercellular communication by the transportation of different biomolecules, such as miRNA, proteins, DNA, mRNA, and lipids, between heterogeneous cell subpopulations. This communication mediated by EVs significantly impacts multiple aspects of pancreatic cancer pathogenesis, including proliferation, angiogenesis, metastasis, and resistance to therapy. In this review, we delve into the pivotal role of EV-associated miRNAs in the progression, metastasis, and development of drug resistance in pancreatic cancer as well as their therapeutic potential as biomarkers and drug-delivery mechanisms for the management of pancreatic cancer. Full article
(This article belongs to the Special Issue Oncogenesis of Pancreatic Cancer: Where Are We)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

14 pages, 2101 KiB  
Systematic Review
Fatty Pancreas Is a Risk Factor for Pancreatic Cancer: A Systematic Review and Meta-Analysis of 2956 Patients
by Mónika Lipp, Dorottya Tarján, Jimin Lee, Ádám Zolcsák, Eszter Szalai, Brigitta Teutsch, Nándor Faluhelyi, Bálint Erőss, Péter Hegyi and Alexandra Mikó
Cancers 2023, 15(19), 4876; https://doi.org/10.3390/cancers15194876 - 7 Oct 2023
Cited by 1 | Viewed by 1879
Abstract
Pancreatic cancer (PC) is one of the most lethal cancers worldwide. Recently, fatty pancreas (FP) has been studied thoroughly, and although its relationship to PC is not fully understood, FP is suspected to contribute to the development of PC. We aimed to assess [...] Read more.
Pancreatic cancer (PC) is one of the most lethal cancers worldwide. Recently, fatty pancreas (FP) has been studied thoroughly, and although its relationship to PC is not fully understood, FP is suspected to contribute to the development of PC. We aimed to assess the association between PC and FP by conducting a systematic review and meta-analysis. We systematically searched three databases, MEDLINE, Embase, and CENTRAL, on 21 October 2022. Case–control and cross-sectional studies reporting on patients where the intra-pancreatic fat deposition was determined by modern radiology or histology were included. As main outcome parameters, FP in patients with and without PC and PC in patients with and without FP were measured. Proportion and odds ratio (OR) with a 95% confidence interval (CI) were used for effect size measure. PC among patients with FP was 32% (OR 1.32; 95% CI 0.42–4.16). However, the probability of having FP among patients with PC was more than six times higher (OR 6.13; 95% CI 2.61–14.42) than in patients without PC, whereas the proportion of FP among patients with PC was 0.62 (95% CI 0.42–0.79). Patients identified with FP are at risk of developing PC. Proper screening and follow-up of patients with FP may be recommended. Full article
(This article belongs to the Special Issue Oncogenesis of Pancreatic Cancer: Where Are We)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop